Millions of adults take medication every day to control high blood pressure, often for decades. At the same time, medical cannabis, CBD oils, gummies, tinctures, and other cannabinoid products have become increasingly common. That overlap raises an important question: Can marijuana interact with blood pressure medication?
The answer is more complicated than simply saying cannabis raises or lowers blood pressure. THC and CBD can affect the cardiovascular system differently, cannabis can produce both increases and decreases in blood pressure depending on dose and circumstances, and some cannabinoids can interfere with liver enzymes that metabolize prescription drugs. Certain hypertension medicines may therefore carry more theoretical interaction potential than others. Direct clinical trials testing marijuana alongside individual antihypertensive drugs remain limited, however, so many interaction warnings are based on known pharmacology rather than documented cases of serious harm.
Current evidence supports a cautious conclusion: using cannabis while taking blood pressure medication is not automatically dangerous, but the combination can potentially cause excessive blood-pressure lowering, dizziness, changes in heart rate, or altered drug exposure in some people. High-dose oral CBD deserves particular attention because controlled human research has demonstrated meaningful inhibition of several drug-metabolizing enzymes. People taking multiple cardiovascular medications, older adults, and anyone with heart disease or a history of fainting may have additional reasons for caution.
How Marijuana Can Affect Blood Pressure
Cannabis does not have one predictable effect on blood pressure. The Centers for Disease Control and Prevention states that cannabis can increase heart rate and raise blood pressure immediately after use. THC activates the sympathetic nervous system—the same “fight or flight” system that can increase pulse, cardiac workload, and blood pressure. The American Heart Association similarly reports that THC may increase heart rate and supine blood pressure while affecting vascular function and cardiac oxygen demand.
At other times, cannabis can produce the opposite effect, particularly when someone stands after sitting or lying down. Blood vessels may dilate and blood pressure may fall enough to produce lightheadedness or fainting. In a randomized, double-blind study involving 29 volunteers, both THC infusion and smoked marijuana produced postural dizziness; approximately 28% of participants experienced severe symptoms. This phenomenon is important for anyone already taking medication designed to lower blood pressure because the combination could theoretically make an orthostatic drop more noticeable.
These apparently contradictory effects are one reason marijuana should not be viewed as a natural blood-pressure medication. Blood pressure after cannabis can vary according to THC concentration, CBD concentration, tolerance, route of administration, dose, body position, hydration, other medications, and underlying cardiovascular disease. The American Heart Association has found no established cardiovascular benefit from cannabis and does not recommend marijuana as a treatment for hypertension.
CBD May Lower Blood Pressure Under Some Conditions
CBD receives special attention because, unlike THC, it usually does not cause conventional cannabis intoxication. Some experimental research suggests that sufficiently large doses can lower blood pressure. A randomized crossover study conducted by researchers at the University of Nottingham gave nine healthy men either 600 mg of CBD or placebo. A single CBD dose reduced resting systolic blood pressure by an average of approximately 6 mm Hg, while increasing heart rate and reducing stroke volume. Blood-pressure responses to several stress tests were also lower following CBD.
That result does not establish CBD as a hypertension treatment. The study involved only nine healthy young men, used a large 600-mg dose, and measured short-term cardiovascular effects rather than long-term hypertension outcomes. Someone taking 10 or 25 mg of commercial CBD is not necessarily experiencing the same physiological exposure. More importantly, the researchers themselves concluded that additional investigation was necessary before CBD could be considered for cardiovascular treatment.
The study does demonstrate why CBD and antihypertensive medication should not automatically be assumed to have completely independent effects. If a cannabinoid lowers blood pressure while a prescription medication is doing the same thing, dizziness or hypotension could theoretically become more likely. The FDA also warns that CBD can interact with prescription drugs and either increase or decrease their effects.
Cannabis Can Also Affect How Some Medications Are Metabolized
The second potential interaction has nothing directly to do with cannabis lowering blood pressure. THC and CBD are processed through liver enzymes in the cytochrome P450 system, and cannabinoids can sometimes inhibit those same enzymes. If a blood-pressure medicine depends on one of those enzymes for metabolism, cannabinoid use could theoretically change how much medication remains in the bloodstream or how rapidly an active drug or metabolite is produced.
The American Heart Association’s scientific statement identifies several relevant pathways. CBD and THC have demonstrated the potential to affect enzymes including CYP3A4, CYP2C9, CYP2C19, and CYP2D6 under experimental conditions. CYP3A4 is especially relevant because it metabolizes many commonly prescribed drugs, including some calcium-channel blockers. CYP2D6 is important to drugs such as metoprolol, while CYP2C9 contributes to losartan metabolism.
Real-world interaction evidence is considerably thinner than these laboratory mechanisms might suggest. A 2024 systematic review screened approximately 4,600 reports and identified only 31 reports demonstrating cannabinoid-related pharmacokinetic changes or adverse drug reactions among the narrow-therapeutic-index drugs examined. The best-documented interactions involved medicines such as warfarin, tacrolimus, sirolimus, and valproate rather than ordinary hypertension medications. The authors nevertheless concluded that clinically important cannabinoid interactions are plausible when prescription drugs and cannabinoids share metabolic pathways.
Amlodipine and Marijuana
Amlodipine is one of the most widely prescribed calcium-channel blockers for hypertension. The potential interaction with cannabis involves both pharmacodynamics and drug metabolism. Amlodipine relaxes blood vessels and reduces blood pressure. Cannabis can sometimes cause vasodilation and orthostatic blood-pressure reductions, meaning that using the two together could theoretically produce more dizziness, lightheadedness, or faintness than either substance alone.
There is also a possible metabolic interaction. Amlodipine is primarily metabolized through CYP3A4. The American Heart Association specifically lists dihydropyridine calcium-channel blockers such as amlodipine among medications for which cannabinoid-related CYP3A4 inhibition could potentially increase drug concentrations.
This remains largely a predicted rather than clinically demonstrated marijuana-amlodipine interaction. Controlled trials have not shown that ordinary cannabis use reliably causes dangerous amlodipine accumulation. Nevertheless, someone who develops unusual dizziness, weakness, faintness, or unusually low home blood-pressure readings after beginning cannabis or concentrated CBD should discuss the change with the clinician managing the medication rather than altering the amlodipine dose independently.
Losartan and Other ARBs
Losartan provides one of the more interesting examples because it was directly included in a controlled cannabinoid interaction study. Researchers from the University of Washington, Johns Hopkins University, and Washington State University gave 18 healthy adults a high-dose CBD-dominant cannabis extract containing 640 mg CBD and 20 mg THC, a THC-dominant extract containing 20 mg THC alone, or placebo. Participants then received several medications used as laboratory probes for specific metabolic enzymes, including losartan as a CYP2C9 probe.
The CBD-rich formulation increased exposure to parent losartan by approximately 77% and reduced the ratio of its metabolite to parent drug, consistent with CBD inhibiting CYP2C9-mediated metabolism. The THC-only formulation did not significantly inhibit the enzymes tested. These findings demonstrate that a sufficiently large dose of CBD can alter losartan pharmacokinetics in humans. They do not, however, prove that common CBD doses increase blood-pressure lowering by 77%. Losartan itself is pharmacologically active, while its metabolite EXP3174 is considerably more potent, so changing the balance between the two creates a more complicated clinical effect than simply “more losartan equals lower blood pressure.”
Other angiotensin-receptor blockers, including valsartan and candesartan, have different metabolic profiles, so the losartan finding should not be automatically applied to the entire class. Anyone using a high-dose CBD preparation while taking losartan has more reason to discuss the combination with a pharmacist or physician than someone occasionally consuming a very low-CBD marijuana product.
Metoprolol and Other Beta-Blockers
Beta-blockers such as metoprolol lower heart rate and blood pressure partly by reducing the effects of adrenaline on the cardiovascular system. Metoprolol is particularly sensitive to CYP2D6 activity. FDA prescribing information notes that CYP2D6 inhibitors can increase metoprolol concentrations, and excessive beta-blockade can contribute to slow heart rate, fatigue, dizziness, and hypotension.
Cannabinoid research has generated a potential CYP2D6 concern, and the American Heart Association has listed beta-blockers such as metoprolol among drugs that could theoretically be affected by cannabinoid inhibition. Interestingly, the controlled University of Washington/Johns Hopkins interaction study complicates this prediction: the very large CBD-containing dose inhibited CYP2C19, CYP2C9, CYP3A, and CYP1A2 but did not significantly inhibit CYP2D6 in vivo.
THC can simultaneously increase sympathetic activity, heart rate, and blood pressure immediately after exposure. As a result, the cannabis-beta-blocker relationship may not behave like a simple additive blood-pressure-lowering interaction. Depending on cannabinoid composition and timing, cannabis could potentially produce dizziness or hypotension in one circumstance while causing tachycardia or a temporary pressure increase in another. Direct clinical trials specifically examining metoprolol plus marijuana are lacking.
Lisinopril, ACE Inhibitors, and Marijuana
Lisinopril is different because it does not depend on cytochrome P450 metabolism. FDA drug-label information states that lisinopril does not undergo metabolism and is eliminated unchanged in the urine. This means the CYP inhibition associated with CBD is not expected to raise lisinopril concentrations through the same mechanism potentially relevant to amlodipine or losartan.
A pharmacodynamic interaction remains possible, however. Lisinopril lowers blood pressure by inhibiting the renin-angiotensin system. If cannabis or CBD produces vasodilation or an orthostatic blood-pressure drop at the same time, someone could experience additive lightheadedness, particularly when standing quickly, exercising, becoming dehydrated, or taking other antihypertensive medications.
The same basic distinction applies to several medications that do not rely heavily on CYP metabolism: there may be little reason to expect cannabis to change the actual medication concentration, while the combined cardiovascular effects may still matter.
Diuretics Such as Hydrochlorothiazide
Hydrochlorothiazide lowers blood pressure partly by increasing sodium and water excretion through the kidneys. According to current FDA labeling, hydrochlorothiazide is not metabolized and is eliminated rapidly through the kidneys, meaning CYP inhibition by CBD is unlikely to be its primary marijuana interaction mechanism.
The more practical concern is dehydration and orthostatic symptoms. Diuretics can reduce circulating fluid volume. Cannabis can sometimes produce dizziness or postural blood-pressure changes. A person who becomes dehydrated from hot weather, exercise, illness, alcohol, or inadequate fluid intake while using both may therefore experience stronger lightheadedness than expected.
This does not mean everyone taking hydrochlorothiazide must avoid cannabis. It means symptoms such as repeated dizziness when standing, near-fainting, weakness, or unusually low pressure deserve attention rather than being dismissed as simply part of the marijuana experience.
THC and CBD Should Not Be Treated as the Same Interaction
One of the most useful conclusions from recent research is that CBD-rich and THC-rich products may interact with medications very differently. In the human CYP interaction trial, 20 mg of THC alone did not significantly inhibit any of the measured enzymes. The CBD-dominant preparation containing 640 mg CBD, in contrast, substantially inhibited several enzymes and changed exposure to losartan, midazolam, omeprazole, and caffeine.
This makes product composition extremely important. Smoking a THC-dominant cannabis flower, consuming a 5-mg THC edible, taking a 25-mg CBD gummy, and using several hundred milligrams of pharmaceutical-grade CBD are pharmacologically different situations. A generic warning that “marijuana interacts with blood pressure medicine” hides those differences.
Dose also matters enormously. The strongest human CBD interaction experiment involved 640 mg CBD, considerably more than many over-the-counter CBD users consume. At the same time, some medical CBD regimens can reach hundreds of milligrams per day. The FDA therefore warns that CBD can change how other medicines work and recommends that people using prescription medications discuss CBD with a healthcare professional.
Who May Be at Greater Risk?
The interaction deserves more attention in someone who already has low-normal blood pressure, frequently experiences dizziness when standing, takes several antihypertensive drugs, or uses medications that also slow the heart rate. Older adults may be particularly vulnerable because falls caused by dizziness or fainting can have serious consequences. Kidney disease, dehydration, heart failure, arrhythmias, and other cardiovascular conditions may further change how both antihypertensive medication and cannabis are tolerated.
Cannabis route also matters. The American Heart Association points out that marijuana smoke contains many of the same combustion products present in tobacco smoke and advises clinicians to consider these cardiovascular exposures when discussing cannabis use. Smoking and vaping can also deliver THC rapidly, producing a faster cardiovascular response than many oral products.
Someone taking medication because of significant cardiovascular disease should therefore not assume that “medical marijuana” automatically makes cannabis cardiovascularly benign. The cannabinoid may have been recommended for pain, nausea, sleep, or another symptom, while still having cardiovascular effects relevant to hypertension treatment.
Blood Pressure Monitoring Can Help Identify a Problem
The 2025 ACC/AHA multisociety hypertension guideline emphasizes home blood-pressure monitoring as an important part of improving hypertension control. For most adults undergoing hypertension treatment, the general guideline target is below 130/80 mm Hg, although individual circumstances can modify that goal.
Home monitoring can be particularly informative when someone begins or substantially changes cannabis use. Rather than drawing conclusions from a single measurement, blood pressure can be checked under consistent conditions over several days. A sudden pattern of readings substantially below a person’s usual range, recurrent dizziness, or major pressure spikes after cannabis are more useful signals than an isolated number taken immediately after an unusual event.
Severe symptoms require more attention. Fainting, chest pain, severe shortness of breath, neurological symptoms, or persistent palpitations warrant prompt medical evaluation. The 2025 hypertension guideline defines severe hypertension as blood pressure above 180/120 mm Hg and calls for timely clinical evaluation and treatment, with emergency assessment when acute target-organ symptoms are present.
Do Not Stop Blood Pressure Medication Because You Use Marijuana
One of the potentially dangerous responses to a suspected cannabis interaction is reducing or stopping prescription medication without medical guidance. Controlled blood pressure can rise again when treatment is withdrawn, and certain drugs carry additional withdrawal concerns. Beta-blockers, for example, should not generally be stopped abruptly because sudden cessation can provoke serious cardiovascular problems in susceptible patients.
Modern hypertension treatment is designed around long-term reduction of stroke, heart attack, heart failure, kidney disease, and other complications. The 2025 ACC/AHA guideline emphasizes consistent treatment and frequently recommends combinations of medications when one agent does not adequately control blood pressure. Cannabis has not been demonstrated to provide equivalent cardiovascular protection and should not be substituted for evidence-based antihypertensive therapy simply because a home blood-pressure reading falls after marijuana or CBD use.
If cannabis appears to change blood pressure substantially, the more appropriate response is to review the situation with the prescribing clinician or pharmacist. Important details include the medication name and dose, THC and CBD amounts, frequency of cannabis use, route of administration, home blood-pressure readings, and symptoms such as dizziness or palpitations.
Final Thoughts on Marijuana and Blood Pressure Medication
Marijuana can interact with blood pressure treatment through two different mechanisms. First, cannabis itself can alter cardiovascular physiology. THC may temporarily increase heart rate and blood pressure, while cannabis can also cause vasodilation and orthostatic dizziness. CBD has reduced blood pressure in a small controlled human experiment. When these effects overlap with prescription antihypertensive therapy, some people may experience excessive dizziness, low blood pressure, or unpredictable changes in pulse and pressure.
Second, cannabinoids—particularly large oral doses of CBD—can alter drug-metabolizing enzymes. Human research has demonstrated inhibition of CYP2C9 and CYP3A, pathways relevant to medications such as losartan and amlodipine. The same study found a substantial pharmacokinetic interaction with losartan but no significant CYP2D6 inhibition, illustrating why interaction risks cannot simply be generalized across every blood-pressure medicine.
For drugs such as lisinopril and hydrochlorothiazide that are not extensively metabolized by CYP enzymes, direct metabolic interactions appear less plausible, although additive blood-pressure lowering, dehydration, and dizziness remain possible. For amlodipine, losartan, metoprolol, and other metabolically processed cardiovascular drugs, cannabinoid composition and dose deserve greater consideration.
The evidence therefore does not support a blanket claim that marijuana cannot be used with blood pressure medication, nor does it establish that every combination is safe. The most sensible approach is individualized: know which antihypertensive medication is being taken, distinguish THC from CBD, pay attention to dose, monitor blood pressure when cannabis use changes, and involve the prescribing clinician or pharmacist when high-dose or frequent cannabinoid use overlaps with cardiovascular treatment.
